Correction to “Clinical Outcomes in Patients Switching From Agalsidase Beta to Migalastat: A Fabry Registry Analysis”

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Inherited Metabolic Disease Pub Date : 2025-03-25 DOI:10.1002/jimd.70023

{"title":"Correction to “Clinical Outcomes in Patients Switching From Agalsidase Beta to Migalastat: A Fabry Registry Analysis”","authors":"","doi":"10.1002/jimd.70023","DOIUrl":null,"url":null,"abstract":"A. Pisani, K. M. Wilson, J. L. Batista, et al., “Clinical Outcomes in Patients Switching from Agalsidase Beta to Migalastat: A Fabry Registry Analysis,” Journal of Inherited Metabolic Disease 47, no. 5 (2024): 1080–1095, https://doi.org/10.1002/jimd.12773.Note: For each outcome, the model includes patients with at least 1 record in each of the pre- and post-switch periods; sample sizes are the same as those shown for Classic and Late-onset patients in Table 2. Each model includes interaction terms to allow slopes to vary by time period (pre/post switch) and phenotype, is adjusted for age at switch date (continuous) and sex, and includes random intercepts. To visually display estimated trajectories over time for each phenotype, estimated values are shown for a male, aged 50 years at the switch date. The slopes of the lines indicate the estimated annual change in the outcome during each time period. Estimated slopes are the same regardless of sex or age.We apologize for this error.","PeriodicalId":16281,"journal":{"name":"Journal of Inherited Metabolic Disease","volume":"48 2","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jimd.70023","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Inherited Metabolic Disease","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jimd.70023","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

A. Pisani, K. M. Wilson, J. L. Batista, et al., “Clinical Outcomes in Patients Switching from Agalsidase Beta to Migalastat: A Fabry Registry Analysis,” Journal of Inherited Metabolic Disease 47, no. 5 (2024): 1080–1095, https://doi.org/10.1002/jimd.12773.

Note: For each outcome, the model includes patients with at least 1 record in each of the pre- and post-switch periods; sample sizes are the same as those shown for Classic and Late-onset patients in Table 2. Each model includes interaction terms to allow slopes to vary by time period (pre/post switch) and phenotype, is adjusted for age at switch date (continuous) and sex, and includes random intercepts. To visually display estimated trajectories over time for each phenotype, estimated values are shown for a male, aged 50 years at the switch date. The slopes of the lines indicate the estimated annual change in the outcome during each time period. Estimated slopes are the same regardless of sex or age.

We apologize for this error.

Abstract Image

查看原文本刊更多论文

对“从Agalsidase转换为Migalastat的患者的临床结果：Fabry注册分析”的更正

A. Pisani， K. M. Wilson， J. L. Batista，等，“从Agalsidase β转换到Migalastat的患者的临床结果：Fabry注册分析”，遗传代谢疾病杂志，第47期。5 (2024): 1080-1095, https://doi.org/10.1002/jimd.12773.Note：对于每个结果，模型包括在转换前后各有至少1条记录的患者；样本量与表2中经典和晚发患者的样本量相同。每个模型都包括相互作用项，允许斜率随时间段（切换前/切换后）和表型而变化，根据切换日期的年龄（连续）和性别进行调整，并包括随机截距。为了直观地显示每种表型随时间的估计轨迹，在转换日期显示了50岁男性的估计值。直线的斜率表示在每个时间段内产出的估计年变化。估计的坡度是相同的，无论性别或年龄。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Inherited Metabolic Disease 医学-内分泌学与代谢

CiteScore

9.50

自引率

7.10%

发文量

117

审稿时长

4-8 weeks

期刊介绍： The Journal of Inherited Metabolic Disease (JIMD) is the official journal of the Society for the Study of Inborn Errors of Metabolism (SSIEM). By enhancing communication between workers in the field throughout the world, the JIMD aims to improve the management and understanding of inherited metabolic disorders. It publishes results of original research and new or important observations pertaining to any aspect of inherited metabolic disease in humans and higher animals. This includes clinical (medical, dental and veterinary), biochemical, genetic (including cytogenetic, molecular and population genetic), experimental (including cell biological), methodological, theoretical, epidemiological, ethical and counselling aspects. The JIMD also reviews important new developments or controversial issues relating to metabolic disorders and publishes reviews and short reports arising from the Society''s annual symposia. A distinction is made between peer-reviewed scientific material that is selected because of its significance for other professionals in the field and non-peer- reviewed material that aims to be important, controversial, interesting or entertaining (“Extras”).